Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
McKinsey
Accenture
McKesson
Mallinckrodt
Moodys
Boehringer Ingelheim
US Department of Justice
Teva

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,741,885

« Back to Dashboard

Which drugs does patent 8,741,885 protect, and when does it expire?

Patent 8,741,885 protects XARTEMIS XR and is included in one NDA.
Summary for Patent: 8,741,885
Title:Gastric retentive extended release pharmaceutical compositions
Abstract: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.
Inventor(s): Devarakonda; Krishna (St. Louis, MO), Guiliani; Michael J (Creve Coeur, MO), Gupta; Vishal K (Hillsborough, NJ), Heasley; Ralph A (Webster Groves, MO), Shelby; Susan (Creve Coeur, MO)
Assignee: Mallinckrodt LLC (Hazelwood, MO)
Application Number:13/473,571
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Process; Dosage form; Use;

Drugs Protected by US Patent 8,741,885

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,741,885

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,658,631 Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Subscribe
9,468,636 Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Subscribe
9,050,335 Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia ➤ Subscribe
9,629,837 Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia ➤ Subscribe
9,433,582 Gastric retentive extended release pharmaceutical compositions ➤ Subscribe
8,790,694 Gastric retentive extended release pharmaceutical compositions ➤ Subscribe
8,858,963 Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Subscribe
8,992,975 Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Subscribe
9,539,328 Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Moodys
UBS
Federal Trade Commission
McKinsey
Baxter
Teva
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot